Format

Send to

Choose Destination
Cancer Invest. 2015;33(8):347-53. doi: 10.3109/07357907.2015.1047504. Epub 2015 Jul 2.

Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?

Author information

1
a Cancer Research Unit, Clinical Trials Unit , University of Warwick , Coventry , UK.
2
b Faculty of Medicine & Health , University of Leeds , Leeds , UK.
3
c St James's Institute of Oncology , Leeds Teaching Hospitals , Leeds , UK.
4
d University Department of Medical Oncology, Churchill Hospital , Oxford , UK.
5
e Edinburgh Cancer Research Centre , University of Edinburgh , Edinburgh , UK.

Abstract

Imatinib therapy has improved outcomes in advanced GISTs. Current guidelines suggest monitoring with CT scanning every 12 weeks. There are no validated biomarkers to assist disease evaluation. We identified 50 patients treated with imatinib for GIST in a single tertiary center. We assessed the prognostic value of D-dimers by Cox regression, and the utility as a biomarker for radiological progression (rPD) using receiver-operator curve (ROC) analysis. In asymptomatic patients with D-dimer levels <1,000 and falling levels, the negative predictive value for rPD was 92%. D-dimers may reduce the burden of CT scanning in a proportion of patients in this setting.

KEYWORDS:

Biomarker; D-dimer; GIST; Gastrointestinal Stromal Tumor

PMID:
26135352
DOI:
10.3109/07357907.2015.1047504
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for White Rose Research Online
Loading ...
Support Center